Genprex, Inc.

Item5. Other Information

Other Information–* Nasdaq Compliance Matters*

On* August 12, 2025,we received a letter (the “Letter”) from the Listing Qualifications Staff (the “Staff”) of The Nasdaq Stock Market LLC (“Nasdaq”) indicating that, because we havenot* regained compliance with the*$1.00* minimum bid price requirement set forth in Nasdaq Listing Rule5550(a)(2) for continued listing on The Nasdaq Capital Market (the “Bid Price Requirement”) and our ineligibility for asecond 180 calendar day compliance period, the Staff had determined to delist our securities from Nasdaq unless we timely request a hearing before the Nasdaq Hearings Panel (the “Panel”). The Bid Price Requirement of the Nasdaq Listing Rules requires listed securities to maintain a minimum bid price of*$1.00* per share and, as previously disclosed, on* February 7, 2025,Nasdaq had notified us that based upon the closing bid price of our common stock for the last30* consecutive business days, weno longer met the Bid Price Requirement. In accordance with Listing Rule5810(c)(3)(A), Nasdaq had provided us180 calendar days, or until* August 6, 2025,to regain compliance with the Bid Price Requirement. We havenot* regained compliance with the Bid Price Requirement during such180 calendar day period and, because we donot meet Nasdaq’s*$5,000,000* minimum stockholders’ equity initial listing requirement, the Staff determined that we werenot eligible for an additional180-day extension to meet the Bid Price Requirement.

We fully intend to timely request a hearing before the Panel, at which hearing we will request an extension within which to evidence compliance with the Bid Price Requirement. Our request for a hearing will stay any suspension or delisting action by the Staff pending the hearing and the expiration of any additional extension period granted by the Panel following the hearing. We intend to continue to take definitive steps in an effort to evidence compliance with the Bid Price Requirement, including by effecting a reverse stock split. However, there can beno assurance that the Panel will grant our request for continued listing or that we will be able to evidence compliance with the Bid Price Requirement within any extension period that* may*be granted by the Panel or maintain compliance with the other Nasdaq listing requirements.

We, by filing this disclosure in this Item5 of this Form10-Q, disclose our receipt of the Letter from Nasdaq in accordance with Nasdaq Listing Rule5810(b).

Rule 10b5-1 Trading Arrangements and Non-Rule 10b5-1 Trading Arrangements

During the fiscal quarter ended* June 30, 2025*, none of our officers or directors, as those terms are defined in Rule16a-1(f), adopted or terminated a “Rule10b5-1 trading arrangement” or a “non-Rule10b5-1 trading arrangement,” as those terms are defined in Item408 of Regulation S-K.